David A. Siegel Aclaris Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 350,100 shares of ACRS stock, worth $882,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares

350,100

Previous 764,300 54.19%

Holding current value

$882,252

Previous $1.09 Million 38.71%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.41 - $2.13 $584,022 - $882,246	-414,200 Reduced 54.19%	350,100 $665,000
Q2 2025 Aug 14, 2025	SELL	$1.08 - $1.63 $101,628 - $153,383	-94,100 Reduced 10.96%	764,300 $1.09 Million
Q1 2025 May 15, 2025	SELL	$1.53 - $2.6 $182,070 - $309,400	-119,000 Reduced 12.18%	858,400 $1.31 Million
Q4 2024 Feb 14, 2025	SELL	$1.15 - $4.59 $372,715 - $1.49 Million	-324,100 Reduced 24.9%	977,400 $2.42 Million
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.4 $151,648 - $189,560	-135,400 Reduced 9.42%	1,301,500 $1.47 Million

Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $14,342 - $19,312	-14,200 Reduced 0.98%	1,436,900 $1.58 Million
Q1 2024 May 15, 2024	BUY	$0.92 - $1.44 $27,692 - $43,344	30,100 Added 2.12%	1,451,100 $1.8 Million
Q4 2023 Feb 14, 2024	BUY	$0.64 - $6.49 $816,000 - $8.27 Million	1,275,000 Added 873.29%	1,421,000 $1.49 Million
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $798,352 - $1.33 Million	121,700 Added 500.82%	146,000 $1 Million
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $127,818 - $172,368	-16,200 Reduced 40.0%	24,300 $251,000
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $286,335 - $726,975	40,500 New	40,500 $327,000
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $129,542 - $238,336	-13,300 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $38,037 - $57,318	-3,100 Reduced 18.9%	13,300 $193,000
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $759,984 - $1.07 Million	-56,800 Reduced 77.6%	16,400 $295,000
Q2 2021 Aug 16, 2021	BUY	$17.08 - $29.6 $220,331 - $381,840	12,900 Added 21.39%	73,200 $1.29 Million
Q1 2021 May 17, 2021	BUY	$5.86 - $27.73 $76,766 - $363,263	13,100 Added 27.75%	60,300 $1.52 Million
Q4 2020 Feb 16, 2021	BUY	$2.65 - $7.61 $63,600 - $182,640	24,000 Added 103.45%	47,200 $305,000
Q3 2020 Nov 16, 2020	SELL	$1.5 - $2.71 $4,050 - $7,317	-2,700 Reduced 10.42%	23,200 $60,000
Q2 2020 Aug 14, 2020	SELL	$1.04 - $1.73 $9,152 - $15,224	-8,800 Reduced 25.36%	25,900 $42,000
Q1 2020 May 15, 2020	SELL	$0.75 - $2.18 $17,400 - $50,576	-23,200 Reduced 40.07%	34,700 $36,000
Q4 2019 Feb 14, 2020	SELL	$1.02 - $1.97 $99,042 - $191,287	-97,100 Reduced 62.65%	57,900 $109,000
Q3 2019 Nov 14, 2019	BUY	$0.79 - $2.47 $122,450 - $382,850	155,000 New	155,000 $167,000

Others Institutions Holding ACRS

# of Institutions

104

Shares Held

81.7M

Call Options Held

Put Options Held

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $168M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account